2009
DOI: 10.1590/s1678-91992009000100003
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: ABSTRACT:To be granted a product license, a vaccine must present adequate quality, safety and efficacy. Studies on these criteria often utilize target species in a laboratory setting. Vaccines that had been proven effective during laboratory analysis may not present the same features when sold on a large scale, after encountering field conditions, and furthermore, can even produce complications. Measures are already in place to detect adverse reactions as reported by veterinarians to manufacturers, so that vac… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
6
0

Year Published

2017
2017
2021
2021

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(6 citation statements)
references
References 20 publications
0
6
0
Order By: Relevance
“…Purported mechanisms for which vaccination may cause IMPA is generic to other immune‐mediated diseases and include: disturbance of immunoregulation; non‐targeted immune activation via adjuvants or microbe‐derived “superantigen” exposed to cross‐reactive tissue protein incorporated into vaccine; and molecular mimicry between autoantigens and vaccinal microbes (Rashid et al . 2009). However, in this specific individual dog, the clinical signs of IMPA were not self‐limiting, and the dog required a protracted course of immunosuppressive therapy.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Purported mechanisms for which vaccination may cause IMPA is generic to other immune‐mediated diseases and include: disturbance of immunoregulation; non‐targeted immune activation via adjuvants or microbe‐derived “superantigen” exposed to cross‐reactive tissue protein incorporated into vaccine; and molecular mimicry between autoantigens and vaccinal microbes (Rashid et al . 2009). However, in this specific individual dog, the clinical signs of IMPA were not self‐limiting, and the dog required a protracted course of immunosuppressive therapy.…”
Section: Discussionmentioning
confidence: 99%
“…This dog had a relapse of IMPA shortly after an annual vaccination, and its first occurrence of IMPA was possibly also after recent vaccination (the medical record for this dog did not specify the precise date of recent vaccination for its first onset of IMPA). Purported mechanisms for which vaccination may cause IMPA is generic to other immune-mediated diseases and include: disturbance of immunoregulation; non-targeted immune activation via adjuvants or microbe-derived "superantigen" exposed to cross-reactive tissue protein incorporated into vaccine; and molecular mimicry between autoantigens and vac-cinal microbes ( Rashid et al . 2009 ).…”
Section: Discussionmentioning
confidence: 99%
“…Second, vaccination may cause adverse reactions in vaccinated animals. This means a vaccine may cause some adverse side effects (e.g., anaphylaxis, decrease in production traits) to a recipient [ 2 , 3 ]. Third, mass vaccination campaigns can be very expensive and may be unprofitable for some livestock farmers [ 84 ].…”
Section: Farm Animal Diseases: Influence Prevalence and Controllmentioning
confidence: 99%
“…Vaccination, medical treatment, and eradication strategy are common methods to control health issues caused by diseases. These methods, however, are facing some bottlenecks, such as the side effects of vaccination [ 2 , 3 ], public concerns about residual drugs and drug resistance after employing medical treatment [ 4 , 5 , 6 , 7 , 8 , 9 ], and financial cost and high recurrence rate of using eradication strategies [ 10 , 11 ]. Several other methods including genome editing, biosensor, and probiotics provide animal farming industries more options to enhance animal health.…”
Section: Introductionmentioning
confidence: 99%
“…Improper time of administration of vaccine, such as during acute infection with wild-type virus and concurrent administration of MLV vaccine or in otherwise unhealthy animals Improper storage and/or handling of vaccine (ie, temperature, UV light, excessive shaking, expiration) Disrupted physiologic and immunologic status of cattle being vaccinated Manufacturing errors that may compromise safety of a particular lot group of vaccine 28 Based on the segmented structure of the beef industry, millions of cattle annually enter the feedlot considered high-risk; however, the USDA approval process does not require examining the safety of vaccination in highly stressed, immunosuppressed cattle. 28 In fact, the USDA CVM Web site states, "Products are shown to be effective in healthy animals. A protective immune response may not be elicited if animals are incubating an infectious disease, are malnourished or parasitized, are stressed due to shipment or environmental conditions, are otherwise immunocompromised, or the vaccine is not administered in accordance with label directions."…”
Section: Vaccine Safetymentioning
confidence: 99%